Forecast
The analysts' average price target is €13.48 (-53.77%). The median is €14.58 (-50.00%).
| Buy |
6 |
| Hold |
15 |
| Sell |
1 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
In the last year, ImmunoGen had revenue of €101.41M and net profit of -€207.83M
| (EUR) | 2022 | YoY |
|---|---|---|
| Revenue | 101.41M | 65.08% |
| Gross profit | 101.25M | 64.82% |
| Net profit | -207.83M | 69.65% |
| EBITDA | -201.15M | 71.82% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €7.95B |
Number of shares | 279.35M |
52-week high/low | €28.48 - €3.29 |
| Dividends | No |
Beta | 1.17 |
P/E ratio | -35.54 |
PEG ratio | -0.52 |
P/B ratio | 50.84 |
P/S ratio | 80.21 |
Company profile
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
| Name | ImmunoGen |
| CEO | Mark Joseph Enyedy |
| Headquarters | Waltham,
ma USA |
| Website | |
| Sector | Health Care |
| Industry | Biotechnology |
| IPO | 11/17/1989 |
| Employees | 277 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | IMGN |